ZyVersa Therapeutics, Inc. (ZVSA) Balance Sheet
ZVSA balance sheet, 2025
December 31, 2025 · U.S. dollars$347.9M assets = $12.73B liabilities + −$12.39B equity
Liabilities exceed assets: shareholders’ equity is negative (−$12.39B).
Both columns are drawn to the same scale: what ZVSA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ZVSA financial health
Descriptive bands, not a rating. Fiscal 2025.
ZVSA balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $685,5672020 | $347.9M2025 | +247.6%/yr | |
| Total liabilities | $9.2M2020 | $12.73B2025 | +324.5%/yr | |
| Shareholders’ equity | −$8.6M2020 | −$12.39B2025 | — | |
| Cash & short-term investments | $174,6702020 | $101.8M2025 | +257.3%/yr | |
| Total debt | $3.8M2020 | $8,6562023 | −86.9%/yr | |
| Net cash (debt) | −$3.6M2020 | $3.1M2023 | +$6.8M | |
| Working capital | −$7.2M2020 | −$12.39B2025 | −$12.4B | |
| Current ratio | 0.042020 | 0.032025 | −0.02 | |
| Debt / equity | 0.002022 | 0.002023 | 0.00 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ZVSA assets
ZVSA liabilities and equity
ZVSA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ZVSA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $101.8M | $1.5M | $3.1M | $5.9M | $328,581 | $174,670 |
| Cash & equivalents | $101.8M | $1.5M | $3.1M | $5.9M | $328,581 | $174,670 |
| Short-term investments | — | $1.53B | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $246.1M | $184,873 | $215,459 | $460,347 | $483,201 | $164,440 |
| Total current assets | $347.9M | $1.7M | $3.4M | $6.4M | $811,782 | $339,110 |
| Property, plant & equipment (net) | $0 | $0 | $14,772 | $115,704 | $27,733 | $38,133 |
| Goodwill & intangible assets | $0 | $18.6M | $18.6M | $112.0M | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $235,714 | $98,476 | $46,659 | $286,659 | $308,324 |
| Total assets | $347.9M | $20.6M | $22.1M | $118.5M | $1.1M | $685,567 |
| Liabilities | ||||||
| Accounts payable | $10.1M | $9.3M | $8.4M | $6.0M | $2.0M | $2.3M |
| Short-term debt | — | — | $8,656 | $108,756 | $9.2M | $2.1M |
| Deferred revenue | — | — | — | — | $16,913 | $20,502 |
| Total current liabilities | $12.73B | $11.2M | $10.2M | $8.2M | $13.6M | $7.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $1.7M |
| Lease obligations | — | $0 | $8,656 | $108,756 | $0 | — |
| Other long-term liabilities | $0 | $851,658 | $844,913 | $10.3M | $11.2M | $0 |
| Total liabilities | $12.73B | $12.1M | $11.0M | $18.5M | $13.6M | $9.2M |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $809 | $251 | $405 | $902 | $242 | $242 |
| Retained earnings (deficit) | −$137.6M | −$112.6M | −$103.2M | −$4.9M | −$52.9M | −$44.8M |
| Accumulated other comprehensive income | — | — | −$1,000 | — | −$75.8M | −$331,331 |
| Total shareholders' equity | −$12.39B | $8.5M | $11.1M | $100.0M | −$12.5M | −$8.6M |
| Key figures | ||||||
| Total debt | — | — | $8,656 | $108,756 | $9.2M | $3.8M |
| Net cash (debt) | — | — | $3.1M | $5.8M | −$8.8M | −$3.6M |
| Working capital | −$12.39B | −$9.5M | −$6.8M | −$1.8M | −$12.8M | −$7.2M |
| Tangible book value | −$12.39B | −$10.1M | −$7.6M | −$12.0M | −$12.5M | −$8.6M |
| Book value per share | −$2,076.95 | — | — | — | — | — |
| Shares outstanding | 6.0M | — | — | — | — | — |
| Current ratio | 0.03 | 0.15 | 0.33 | 0.78 | 0.06 | 0.04 |
| Quick ratio | 0.01 | 0.14 | 0.31 | 0.72 | 0.02 | 0.02 |
| Debt / equity | — | — | 0.00 | 0.00 | — | — |
| Equity / assets | −3,560.4% | 41.3% | 50.1% | 84.4% | −1,110.0% | −1,248.3% |
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $302.7M | $101.8M | $527,978 | $72,086 | $1.6M | $1.5M | $122,921 | $119,486 | $2.0M | $3.1M | $1.6M | $228,693 |
| Cash & equivalents | $302.7M | $101.8M | $527,978 | $72,086 | $1.6M | $1.5M | $122,921 | $119,486 | $2.0M | $3.1M | $1.6M | $228,693 |
| Short-term investments | — | — | — | — | — | $1.53B | $122.8M | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $439.6M | $246.1M | $467,555 | $476,983 | $498,778 | $184,873 | $267,494 | $521,906 | $866,476 | $215,459 | $426,519 | $886,911 |
| Total current assets | $742.2M | $347.9M | $995,533 | $549,069 | $2.1M | $1.7M | $390,415 | $641,392 | $2.9M | $3.4M | $2.0M | $1.1M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1,733 | $4,333 | $14,772 | $40,611 | $66,031 |
| Goodwill & intangible assets | $0 | $0 | $0 | $18,648 | $18.6M | $18.6M | $18.6M | $18.6M | $18.6M | $18.6M | $30.8M | $11.93B |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $44,727 | $19.1M | $227,328 | $235,714 | $385,606 | $178,476 | $98,476 | $98,476 | $0 | $0 |
| Total assets | $742.2M | $347.9M | $1.0M | $19.6M | $21.0M | $20.6M | $19.4M | $19.5M | $21.7M | $22.1M | $32.9M | $32.0M |
| Liabilities | ||||||||||||
| Accounts payable | $10.2M | $10.1M | $9.8M | $9.8M | $9.6M | $9.3M | $9.3M | $8.3M | $8.1M | $8.4M | $8.9M | $8.1M |
| Short-term debt | $1.20B | — | — | — | — | — | — | — | $8,656 | $8,656 | $34,349 | $59,625 |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | $2.3M | $1.8M |
| Total current liabilities | $14.87B | $12.73B | $12.8M | $12.7M | $12.0M | $11.2M | $11.5M | $10.0M | $9.6M | $10.2M | $11.7M | $10.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | $0 | $0 | $0 | $0 | $8,656 | $34,349 | $59,625 |
| Other long-term liabilities | $0 | $0 | $0 | $851,659 | $851,658 | $851,658 | $854,620 | $854,620 | $844,914 | $844,913 | $1.4M | $1.4M |
| Total liabilities | $14.87B | $12.73B | $12.8M | $13.5M | $12.9M | $12.1M | $12.4M | $10.8M | $10.4M | $11.0M | $13.1M | $11.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $809 | $809,000 | $1,618 | $487 | $257 | $251 | $107 | $83 | $83 | $405 | $4,353 | $2,367 |
| Retained earnings (deficit) | −$139.4M | −$137.58B | −$136.9M | −$117.1M | −$114.9M | −$112.6M | −$111.2M | −$108.8M | −$106.0M | −$103.2M | −$89.9M | −$87.0M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | −$1,000 | −$1,000 | −$405 | — | −$104.15B |
| Total shareholders' equity | −$14.1M | −$12.39B | −$11.7M | $6.1M | $8.1M | $8.5M | $7.0M | $8.6M | $11.2M | $11.1M | $19.7M | $20.1M |
| Key figures | ||||||||||||
| Total debt | $1.20B | — | — | — | — | — | — | — | $8,656 | $8,656 | $34,349 | $59,625 |
| Net cash (debt) | −$897.3M | — | — | — | — | — | — | — | $2.0M | $3.1M | $1.5M | $169,068 |
| Working capital | −$14.12B | −$12.39B | −$11.8M | −$12.1M | −$9.9M | −$9.5M | −$11.2M | −$9.4M | −$6.7M | −$6.8M | −$9.7M | −$9.4M |
| Tangible book value | −$14.1M | −$12.39B | −$11.7M | $6.1M | −$10.5M | −$10.1M | −$11.6M | −$10.0M | −$7.4M | −$7.6M | −$11.1M | −$11.91B |
| Book value per share | −$1.74 | −$2,076.95 | — | — | $2.62 | — | — | — | — | — | — | — |
| Shares outstanding | 8.1M | 6.0M | — | — | 3.1M | — | — | — | — | — | — | — |
| Current ratio | 0.05 | 0.03 | 0.08 | 0.04 | 0.18 | 0.15 | 0.03 | 0.06 | 0.30 | 0.33 | 0.17 | 0.11 |
| Quick ratio | 0.02 | 0.01 | 0.04 | 0.01 | 0.13 | 0.14 | 0.01 | 0.01 | 0.21 | 0.31 | 0.13 | 0.02 |
| Debt / equity | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | −1.9% | −3,560.4% | −1,127.2% | 31.1% | 38.7% | 41.3% | 36.2% | 44.3% | 51.8% | 50.1% | 60.0% | 62.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
ZVSA financial position
At the end of fiscal 2025 (December 31, 2025), ZyVersa Therapeutics had total assets of $347.9 million (up 1,588.9% from a year earlier), total liabilities of $12.7 billion and shareholders' equity of -$12.4 billion. Its current ratio was 0.03. In the latest quarter (ended March 31, 2026) total assets were $742.2 million and equity -$14.1 million.
Related: ZVSA income statement, ZVSA cash flow statement, ZVSA key metrics. See the ZVSA stock overview for the latest quote and news.
ZVSA balance sheet FAQ
What are ZyVersa Therapeutics's total assets?
ZyVersa Therapeutics reported total assets of $347.9 million at the end of fiscal 2025 (December 31, 2025), compared with $20.6 million a year earlier.
How much cash does ZyVersa Therapeutics have?
ZyVersa Therapeutics held $101.8 million in cash and short-term investments at the end of fiscal 2025.
What is ZyVersa Therapeutics's book value?
ZyVersa Therapeutics's shareholders' equity (book value) was -$12.4 billion at the end of fiscal 2025, or −$2,076.95 per share.
What is ZyVersa Therapeutics's current ratio?
ZyVersa Therapeutics had current assets of $347.9 million and current liabilities of $12.7 billion, a current ratio of 0.03 (current liabilities exceed current assets).